AI Article Synopsis
Article Abstract
Burgess et al ( 1 ) present intriguing results of repetitive transient opening of the blood-brain barrier (BBB) in a transgenic mouse model of advanced Alzheimer disease (AD). The results underscore the potential of using magnetic resonance (MR) imaging-guided focused ultrasound and microbubble ultrasonography (US) contrast agents for the disruption of the BBB as a potential long-term therapy to reduce amyloid plaque burden and improve cognitive performance. This daring conclusion that is based on an experimental animal model should now be confirmed in humans. Considering that the technology is commercially available and given the immense clinical need, clinical trials in this AD treatment should be initiated as soon as possible.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1148/radiol.14142033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization of focused ultrasound blood-brain barrier disruption effect on inflammation as a function of treatment parameters.
Biomed Pharmacother
December 2024
Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address:
The technology of focused ultrasound-mediated disruption of the blood-brain barrier (FUS-BBB opening) has now been used in over 20 Phase 1 clinical trials to validate the safety and feasibility of BBB opening for drug delivery in patients with brain tumors and neurodegenerative diseases. The primary treatment parameters, FUS intensity and microbubble dose, are chosen to balance sufficient BBB disruption to achieve drug delivery against potential acute vessel damage leading to microhemorrhage. However, other safety considerations due to second order effects caused by BBB disruption, such as inflammation and alteration of neurovascular function, are only beginning to be understood.
View Article and Find Full Text PDFA comparative study of experimental and simulated ultrasound beam propagation through cranial bones.
Phys Med Biol
December 2024
Department of Medical Physics and Bioengineering, University College London, Gower Street, London, WC1E 6BT, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND.
Transcranial ultrasound is used in a variety of treatments, including neuromodulation, opening the blood-brain barrier (BBB), and high intensity focused ultrasound (HIFU) therapies. To ensure safety and efficacy of these treatments, numerical simulations of the ultrasound field within the brain are used for treatment planning and evaluation. This study investigates the accuracy of numerical modelling of the propagation of focused ultrasound through cranial bones.
View Article and Find Full Text PDFDecoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer's, Parkinson's, and ALS.
Int J Mol Sci
November 2024
Department of Anatomy, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Neurodegenerative diseases, such as Alzheimer's, Parkinson's, ALS, and Huntington's, remain formidable challenges in medicine, with their relentless progression and limited therapeutic options. These diseases arise from a web of molecular disturbances-misfolded proteins, chronic neuroinflammation, mitochondrial dysfunction, and genetic mutations-that slowly dismantle neuronal integrity. Yet, recent scientific breakthroughs are opening new paths to intervene in these once-intractable conditions.
View Article and Find Full Text PDFLipid nanoparticles and transcranial focused ultrasound enhance the delivery of SOD1 antisense oligonucleotides to the murine brain for ALS therapy.
J Control Release
December 2024
School of Chemistry and Molecular Bioscience, Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2522, Australia. Electronic address:
Article Synopsis
- ALS is a severe neurodegenerative disease characterized by the buildup of misfolded proteins in motor neurons, prompting researchers to find ways to reduce this burden for potential treatment.
- Antisense oligonucleotides (ASOs) have been identified as a promising option to target proteins like SOD1 that cause mutations, but their delivery to the central nervous system is challenging due to the blood-brain barrier.
- The study demonstrates that using transcranial focused ultrasound (FUS) along with calcium phosphate lipid nanoparticles significantly enhances the delivery of a SOD1 ASO into the brain of mice, leading to reduced SOD1 levels and improved motor neuron survival without damaging brain tissue.
The potential of circulating nonesterified fatty acids and sphingolipids in the biological understanding of cognitive decline and dementia.
Curr Opin Lipidol
December 2024
Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark.
Purpose Of Review: Cognitive decline and late-onset dementia pose significant challenges in aging societies, and many dementia cases could be prevented or delayed through modification of associated risk factors, many of which are tied to cardiovascular and metabolic dysfunction. As individuals age, the blood-brain barrier becomes more permeable, easing the exchange of molecules between the bloodstream and the brain. Consequently, blood-based biological markers (so-called biomarkers) provide a minimally invasive and accessible means of accessing molecular changes associated with aging and neurodegeneration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!